Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes

Stroke

Volumn 27, Issue 1, 1996, Pages 63-68

  Lehto, Seppo ^a   Rönnemaa, Tapani ^b   Pyörälä, Kalevi ^a   Laakso, Markku ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

diabetes mellitus; glucose; mortality; risk factors

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FINLAND; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030030190     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.1.63     Document Type: Article

References (41)

1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524.
2. Stokes J, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation. 1987;75:65-73.
3. Alex M, Baron EK, Goldenberg S, Blumenthal HT. An autopsy study of cerebrovascular accident in diabetes mellitus. Circulation. 1962;25:663-673.
4. Lavy S, Melamed E, Cahane E, Carmon A. Hypertension and diabetes as risk factors in stroke patients. Stroke. 1973;4:751-759.
5. Yudkin JS. Factors influencing threshold and choice of treatment for hypertension in NIDDM: cardiovascular factors. Diabetes Care. 1991;14(suppl 4):27-32.
6. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke. 1991;22: 312-318.
7. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA. 1988;259:1025-1029.
8. Bierman EL. Atherosclerosis in diabetes. Arterioscler Thromb. 1992; 12:647-656.
9. Kuusisto J, Mykkänen L, Pyorälä K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke. 1994;25:1157-1164.
10. Laakso M, Rönnemaa T, Pyörälä K, Kallio V, Puukka P, Penttilä I. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in Finland. Diabetes Care. 1988;11:449-463.
11. Madsbad S, Alberti KG, Binder C, Burrin JM, Faber OK, Krarup T, Regeur L. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J. 1979;2: 1257-1259.
12. World Health Organization. WHO Study Group on Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1985. Technical Report Series No. 727.
13. World Health Organization. Proposal for the Multinational Monitoring of Trends and Determinants in Cardiovascular Disease and Protocol (MONICA Project). Geneva, Switzerland: World Health Organization; 1983. Publication WHO/MNC/82.1, revision 1.
14. Walker AE, Robins M, Weinfeld FD. The National Survey of Stroke: clinical findings. Stroke. 1981;12(part 2, suppl I):I-13-I-44.
15. Faber OK, Binder C. C-peptide response to glucagon: a test for the residual beta cell function in diabetes mellitus. Diabetes. 1977;26: 605-610.
16. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia. 1975;11:541-548.
17. Siedel J, Schlumberger H, Klose S, Ziegenhorn J, Wahlefeld AW. Improved reagent for the enzymatic determination of serum cholesterol. J Clin Chem Clin Biochem. 1981;19:838-839.
18. Kostner G. Enzymatic determination of cholesterol in high density lipoprotein fractions prepared by polyanion precipitation. Clin Chem. 1976;22:695.
19. International Classification of Diseases, 9th Rev. Vol 1: Clinical Modification. Ann Arbor, Mich: Edwards Bros Inc; 1981.
20. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990;13:153-169.
21. Asplund K, Hagg F, Helmers C, Lithner F, Strand T, Wester PO. The natural history of stroke in diabetic patients. Acta Med Scand. 1980;207:417-424.
22. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program, III: reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633-638.
23. Hebert PR, Fiebach NH, Eberlein KA, Taylor JO, Hennekens CH. The community-based randomized trials of pharmacologic treatment of mild to moderate hypertension. Am J Epidemiol. 1988; 127:581-590.
24. Jovanovic L, Peterson CM. The clinical utility of glycosylated hemoglobin. Am J Med. 1981;70:331-338.
25. Bunn HF. Evaluation of glycosylated hemoglobin in diabetic patients. Diabetes. 1981;30:613-617.
26. Ladenson JH, Chan KM, Kilzer P. Glycated hemoglobin and diabetes: a case and overview of the subject. Clin Chem. 1985;31: 1060-1067.
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
28. Colwell JA. Vascular thrombosis in type II diabetes. Diabetes. 1993; 42:8-11. Editorial.
29. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(suppl II): II-3-II-16.
30. Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes. 1992;(suppl 2):67-73.
31. Laakso M, Barrett-Connor E. Asymptomatic hyperglycaemia is associated with lipid and lipoprotein changes favouring atherosclerosis. Arteriosclerosis. 1989;9:665-672.
32. Laakso M, Voutilainen E, Sarlund H, Aro A, Pyörälä K, Penttilä I. Serum lipids and lipoproteins in middle-aged non-insulin dependent diabetics. Atherosclerosis. 1985;56:271-281.
33. Reed D, Yano K, Kagan A. Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer in the Honolulu Heart Program. Am J Med. 1986;80:871-878.
34. Tell GS, Crouse JR, Furberg CD. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis: a review. Stroke. 1988;19:423-430.
35. Murai A, Tanaka T, Miyahara T, Kameyama M. Lipoprotein abnormalities in the pathogenesis of cerebral infarction and transient ischemic attack. Stroke. 1981;12:167-172.
36. Tilvis RS, Erkinjuntti T, Sulkava R, Färkkila M, Miettinen TA. Serum lipids and fatty acids in ischemic strokes. Am Heart J. 1987; 113:615-619.
37. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thrombo-embolic disease. Semin Thromb Hemost. 1990;16:207-216.
38. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994;17:818-823.
39. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
40. Margaglione M, Di-Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb. 1994;14:1741-1745.
41. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol. 1987;9:263-268.